Key Points
- PTC EVP Lee Scott Golden sold 829 shares on April 2 under a pre-arranged Rule 10b5-1 plan for $56,363.71 to cover tax withholding from vested equity, leaving him with 79,115 shares (about $5.38M), a 1.04% ownership reduction.
- Those sales are part of a larger pattern this year — Golden has sold a total of 16,161 shares across multiple transactions (about $1.08M), including a 10,000-share sale on March 5 for $633,800.
- PTC’s recent financials show a significant earnings miss (Q EPS -$1.67 vs. -$0.21 est.) and revenue of $164.7M vs. $281.5M expected (down 22.7% YoY); the stock traded near $68.90 with a $5.7B market cap and a consensus analyst target of $82.71 (average rating: Moderate Buy).
PTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) EVP Lee Scott Golden sold 829 shares of the stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $67.99, for a total transaction of $56,363.71. Following the completion of the sale, the executive vice president directly owned 79,115 shares in the company, valued at approximately $5,379,028.85. The trade was a 1.04% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Lee Scott Golden also recently made the following trade(s):
- On Thursday, March 5th, Lee Scott Golden sold 10,000 shares of PTC Therapeutics stock. The stock was sold at an average price of $63.38, for a total value of $633,800.00.
- On Wednesday, February 18th, Lee Scott Golden sold 2,484 shares of PTC Therapeutics stock. The stock was sold at an average price of $69.36, for a total value of $172,290.24.
- On Thursday, January 8th, Lee Scott Golden sold 866 shares of PTC Therapeutics stock. The stock was sold at an average price of $76.45, for a total value of $66,205.70.
- On Wednesday, January 7th, Lee Scott Golden sold 642 shares of PTC Therapeutics stock. The stock was sold at an average price of $77.48, for a total value of $49,742.16.
- On Tuesday, January 6th, Lee Scott Golden sold 1,340 shares of PTC Therapeutics stock. The stock was sold at an average price of $76.95, for a total value of $103,113.00.
PTC Therapeutics Stock Up 1.7%
PTCT stock opened at $68.90 on Tuesday. PTC Therapeutics, Inc. has a 52-week low of $35.95 and a 52-week high of $87.50. The stock's fifty day simple moving average is $68.91 and its 200-day simple moving average is $71.17. The stock has a market capitalization of $5.70 billion, a price-to-earnings ratio of 8.90 and a beta of 0.55.
PTC Therapeutics (NASDAQ:PTCT - Get Free Report) last issued its earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.67) earnings per share for the quarter, missing analysts' consensus estimates of ($0.21) by ($1.46). PTC Therapeutics had a net margin of 39.44% and a negative return on equity of 362.45%. The firm had revenue of $164.68 million during the quarter, compared to analyst estimates of $281.45 million. During the same quarter in the previous year, the business posted ($0.85) EPS. PTC Therapeutics's revenue was down 22.7% compared to the same quarter last year. As a group, analysts anticipate that PTC Therapeutics, Inc. will post -4.52 earnings per share for the current fiscal year.
Institutional Trading of PTC Therapeutics
Several hedge funds and other institutional investors have recently bought and sold shares of PTCT. Vanguard Group Inc. boosted its stake in PTC Therapeutics by 6.2% in the fourth quarter. Vanguard Group Inc. now owns 8,803,203 shares of the biopharmaceutical company's stock valued at $668,691,000 after acquiring an additional 514,204 shares during the period. Wellington Management Group LLP boosted its stake in PTC Therapeutics by 4.8% in the third quarter. Wellington Management Group LLP now owns 4,918,619 shares of the biopharmaceutical company's stock valued at $301,856,000 after acquiring an additional 224,481 shares during the period. Janus Henderson Group PLC boosted its stake in PTC Therapeutics by 28.6% in the fourth quarter. Janus Henderson Group PLC now owns 4,851,332 shares of the biopharmaceutical company's stock valued at $368,587,000 after acquiring an additional 1,077,776 shares during the period. State Street Corp boosted its stake in PTC Therapeutics by 34.2% in the fourth quarter. State Street Corp now owns 4,206,126 shares of the biopharmaceutical company's stock valued at $319,497,000 after acquiring an additional 1,071,343 shares during the period. Finally, Toronto Dominion Bank boosted its stake in PTC Therapeutics by 27.5% in the fourth quarter. Toronto Dominion Bank now owns 4,138,215 shares of the biopharmaceutical company's stock valued at $314,339,000 after acquiring an additional 891,690 shares during the period.
Analyst Ratings Changes
PTCT has been the topic of several research reports. Jefferies Financial Group lowered PTC Therapeutics from a "buy" rating to a "hold" rating and cut their price objective for the company from $91.00 to $76.00 in a research report on Monday, March 30th. Wells Fargo & Company cut their price objective on PTC Therapeutics from $93.00 to $86.00 and set an "overweight" rating on the stock in a research report on Friday, February 20th. Wall Street Zen lowered PTC Therapeutics from a "buy" rating to a "hold" rating in a research report on Saturday, February 21st. TD Cowen reaffirmed a "hold" rating on shares of PTC Therapeutics in a research report on Thursday, January 29th. Finally, Royal Bank Of Canada dropped their target price on PTC Therapeutics from $87.00 to $82.00 and set a "sector perform" rating on the stock in a research report on Friday, February 20th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $82.71.
Read Our Latest Research Report on PTC Therapeutics
PTC Therapeutics Company Profile
(
Get Free Report)
PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company's research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.
Among PTC's approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
